Gilead shifts cystic fibrosis drug to CURx Pharma in licensing deal By: San Francisco Business Times via Business Journals February 20, 2014 at 15:28 PM EST Gilead Sciences Inc. licensed to CURx Pharmaceuticals a late-stage treatment for lung infection in cystic fibrosis patients... Read More >>